Article Summary
In July 2026, the FDA Pharmacy Compounding Advisory Committee (PCAC) recommended six peptides for inclusion on 503A Bulks List. It is a major step forward, but the peptides are not authorized for compounding yet.Peptide therapy has been front-page news, and for good reason. On July 23-24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides and voted to recommend six of them for the 503A Bulks List, the list of active pharmaceutical ingredients licensed pharmacies can use to compound medications legally.
Empower Pharmacy co-hosted a live webinar with Second Opinion Media called “Peptide Therapy: Where Do We Go From Here?” to explain the import of the recent hearings. The panel included:
- Christina Farr, CEO of Second Opinion Media and general partner at Scrub Capital (moderator)
- Shaun Noorian, founder and CEO of Empower Pharmacy
- Rekha Kumar, senior medical advisor at Found
- Alex Tatum, corporate director of men’s health at U.S. Urology Partners
Here are the five biggest takeaways.
This article summarizes a panel discussion. It is not medical advice. Talk to your provider before starting any new treatment.
1. The FDA Advisory Committee Vote Was a Historic Milestone
On July 23 and 24, 2026, the PCAC voted to recommend six peptides for inclusion on the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. One peptide, emideltide (also called DSIP), was voted down.
If the FDA adopts PCAC’s recommendations, licensed compounding pharmacies could legally compound and dispense these peptide therapies to patients across the United States. Dr. Tatum called the vote “historic,” noting that very few substances have ever been added to the Bulks List.
The vote does not change what pharmacies can legally compound today. It is a recommendation, not a final rule. The FDA still has to decide whether to move forward, and formal rulemaking can take many months.
Why it matters: PCAC recommendations are a step toward greater access to peptide therapies through regulated healthcare channels, rather than unregulated gray-market sources.
2. Peptides Are Tools for Optimizing Health, Not a Replacement for Existing Treatment
One of the clearest messages from the webinar: peptides are not shortcuts, and they don’t replace the basics of good health.
Dr. Kumar explained that peptides are technically chains of amino acids. In practice, she described them as signaling molecules that may help support:
- Recovery and tissue repair
- Sleep quality
- Metabolic function
- Performance
- Overall wellbeing
She was clear that peptide therapy does not replace:
- Nutrition
- Exercise
- Sleep
- Stress management
- Evidence-based medical treatment
Peptides may work best as an additional tool for patients who have already covered the fundamentals and want to go further.
Why it matters: Peptides are not a cure-all. They work best as one part of a broader wellness plan, not a stand-in for it.
3. There’s No One-Size-Fits-All Peptide Protocol
Dr. Tatum’s answer to “What peptide should I take?” is simple: “What’s bothering you?”
Peptide selection depends on a patient’s goals, current health, symptoms, and medical history. Some patients may not be good candidates for peptide therapy at all.
The panel agreed that peptides work best as part of a personalized treatment plan, built together with a knowledgeable provider.
Why it matters: There is no universal peptide protocol. The right choice, if there is one, depends on a patient’s specific health picture and should come from a conversation between a patient and provider.
4. Where You Get Your Peptides Matters More Than People Think
A major concern the panel raised was sourcing. Many patients currently buy peptides from “research use only” (RUO) websites. These sites are not regulated by any government agency.
Compounding pharmacies operate under a different standard. They are required to source ingredients from FDA-registered suppliers and follow United States Pharmacopeia quality standards. Compounded medications are not FDA-approved, but they are made under FDA oversight.
Why it matters: If these peptides are formally added to the Bulks List, patients will have a regulated path to access them instead of relying on unregulated websites.
5. Telehealth Could Accelerate Adoption
The panel expects telemedicine to play a large role in expanding access to peptide therapy.
Just as telehealth helped expand access to GLP-1 therapies, panelists believe peptides could follow a similar path, driven by:
- Demand for convenience
- More awareness through social media
- Growing interest in preventive, personalized-focused care
- Comfort with virtual care
Panelists were careful to note that telehealth isn’t replacing in-person medicine. Instead, they expect virtual and in-person care to serve different needs while expanding access overall.
Why it matters: Telehealth could make peptide therapy easier to access, but it works best alongside, not instead of, hands-on care from a provider.
Looking Ahead
The FDA PCAC’s recommendation is a significant step for peptide therapy, but the story isn’t finished. The FDA still has to make a final decision, and open questions remain about clinical protocols, dosing standards, long-term outcomes, and education for providers and patients.
What is clear: interest in peptide therapy keeps growing. The next phase will need careful collaboration among clinicians, pharmacies, regulators, and patients to make sure these therapies are used safely and responsibly.
If this webinar showed anything, it’s that peptide therapy is no longer a fringe topic. It’s now part of the bigger conversation about personalized medicine, preventive care, and healthy aging.
